

Dear ACEMID Participant,

Welcome to the third edition of our ACEMID participant study newsletter. You are receiving this newsletter because you are currently enrolled in the ACEMID research study.

Recruiting Momentum

Site updates

Queensland: The ACEMID sites currently recruiting in Queensland are the Princess Alexandra Hospital (Brisbane), the Herston Imaging Research Facility (located within the Royal Brisbane Women's Hospital), the Sunshine Coast University Hospital, and Cairns Hospital. A 3D imaging machine is currently being shipped to Mt Isa Hospital, where recruitment is planned to commence later this year.

New South Wales: In New South Wales, the ACEMID sites currently recruiting are Westmead Hospital and Melanoma Institute Australia in Sydney. Further sites are planned for Port Macquarie, Wagga Wagga and Orange.

Victoria: ACEMID sites currently recruiting in Victoria are Bendigo Health, the Alfred Hospital, and the Skin Health Institute in Melbourne. The Peter MacCallum Cancer Centre and Bass Coast Health (Wonthaggi) will begin recruitment later this year.

Current recruitment: To date, we have enrolled over 3,700 participants across 9 study sites (1781 in QLD, 1203 in NSW, and 777 in VIC).

Expression of interest: We have had a huge expression of interest to participate from across Australia with over 12,000 responses to date. We are very grateful to have such a large response to our recruitment calls. Each state is working through their expression of interest list, and our momentum will increase as further sites become operational.

ACEMID in the news

We are thrilled to announce that our research has been featured on 9 News! It is exciting to see the team featured.




Links here:

[Princess Alexandra Hospital](#)
[Westmead Hospital](#)

ACEMID 2023 Annual report

The highlights of the 2023 ACEMID annual report are now available on our website. You can read more about the achievements of ACEMID over the last 12 months here: <https://acemid.centre.uq.edu.au/annual-reports>



FAQ If I provide a saliva sample, do I receive genetic test results?

As part of this study, some participants were given the option to supply a saliva sample for the study team to perform genetic testing. The aim is to look at genes known to be associated with skin cancers, to see if there is a change (mutation) in a gene which increases your risk of these cancers. In rare cases, a gene change that could be associated with an unrelated health condition might be found as part of the testing process. If the gene change is related to a condition for which treatment or prevention is available, we offered you the option of whether to be contacted by mail/email about this result. You will only be contacted about your result if something is found, and if you consented to receive the result.

For those in whom a gene change is found, there can be impacts on your ability to take out some forms of insurance. Private health insurance and life insurance policies for up to \$500,000 are not affected by genetic test results. For life insurance policies larger than \$500,000, insurance companies can use genetic test results to modify premiums or deny insurance. Existing policies are not affected by new genetic test results unless you plan to change your cover, or you do not meet your payment obligations.

More information about genetic tests and life insurance can be found at the following [link](#).

Safe in the Sunshine

Researchers at the ACRF Australian Centre of Excellence in Melanoma Imaging & Diagnosis (ACEMID) have their sun safe initiative – Safe in the Sunshine

Be sure to also visit the website www.safeinthesunshine.org.au and follow [@safeinthesunshine](#) on Instagram and [Facebook](#), for bite-sized facts on skin cancer prevention and early detection.



Continue to see your doctor for skin checks

As a reminder please note that this is a research study and does not replace your usual medical care. Please continue to see your medical practitioner for a clinical skin examination if you notice any changes on your skin, or continue your usual schedule of follow-up visits if this has been recommended by your doctor.

Funding Acknowledgement

This research program would not be possible without the funding from:

AUSTRALIAN
CANCER
RESEARCH
FOUNDATION

